12/9/2021 8:18:00 AM
Sesen Bio Announces Regulatory Path Forward For Vicineum; Expects To Hold Type C Meeting With FDA In Early 2022
11/8/2021 8:06:50 AM
Sesen Bio Q3 EPS $0.36 Vs. Loss/shr $0.19 Last Year
11/1/2021 8:09:03 AM
Sesen Bio Announces Productive CMC Type A Meeting With The FDA
10/12/2021 8:12:41 AM
Sesen Bio Says Welcomes Eun And Chrie O Further Strengthen
capabilities Across CMC And Clinical Teams
8/9/2021 7:15:07 AM
Sesen Bio Q2 Loss/shr Narrows To $0.15 From $0.24 Last Year
8/5/2021 8:20:00 AM
Sesen Bio Announces Partnership With Eczacibasi Pharma Marketing
for Commercialization Of Vicineum In Turkey
8/2/2021 8:08:31 AM
Sesen Bio Appoints Amy Ponpipom As VP Assistant General Counsel
7/20/2021 9:44:43 AM
Sesen Bio And Qilu Pharmaceutical Announce Enrollment Of First Patient In Clinical Trial For Vicineum In China
7/14/2021 8:19:54 AM
Sesen Bio Announces Productive Late-Cycle Meeting With The FDA For Vicineum(tm)
7/2/2021 8:03:43 AM
Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule
6/18/2021 8:04:24 AM
Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
6/2/2021 8:20:25 AM
Sesen Bio Announces Global Supply Agreement For Vicineum With Qilu Pharmaceutical